Immorna Biotherapeutics
PrivateLast Round
Grant
Aug 26, 2024
Total Funding Raised
$118.8M
Company Overview
Immorna Biotherapeutics operates in Healthcare & Life Sciences and is based in Hangzhou. Its latest recorded funding round was a Grant round in August 2024.
Immorna Biotherapeutics is a biotechnology company that develops RNA-based therapeutics and vaccines for infectious diseases, cancer, and autoimmune diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Revenue Share, Government Contracts
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Immorna Biotherapeutics Comparables
Compare Immorna Biotherapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Innorna | 90% | |
| Eli Lilly and Company | 87% | |
| Stemirna Therapeutics | 85% |
For institutional investors. Book with your work email.
Immorna Biotherapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Aug 26, 2024 | ||||
| Series A Extension | Feb 27, 2023 | ||||
| Series A | Feb 1, 2021 |
For institutional investors. Book with your work email.
Immorna Biotherapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Alwin Capital | Pre Seed |
| China Chengtong Fund Management Co., Ltd. | Series A Extension |
| Zheshang Venture Capital | Series A Extension, Series A |
| Hillhouse Investment | Series A Extension |
| Co-Win Ventures | Series A Extension, Series A |
| Tailong Investment | Series A Extension |
| Tigeryeah Capital | Series A Extension |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 26, 2024
$3.8M grant from the Bill & Melinda Gates Foundation.
- Feb 27, 2023
$100M round with participation from China Structural Reform Fund and Hillhouse Investment.
For institutional investors. Book with your work email.
Immorna Biotherapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Immorna Biotherapeutics's valuation, stock price, and market status.
Is Immorna Biotherapeutics a public or private company?
Immorna Biotherapeutics is a private company.
What is the current stock price of Immorna Biotherapeutics?
Immorna Biotherapeutics is a private company, so its shares have no public market price. Caplight tracks Immorna Biotherapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Immorna Biotherapeutics worth (valuation)?
Valuation information for Immorna Biotherapeutics is not publicly available.
Can I buy Immorna Biotherapeutics stock?
Immorna Biotherapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Immorna Biotherapeutics's last funding round?
Immorna Biotherapeutics's most recent funding round was Grant on August 26, 2024.
Who are the main investors in Immorna Biotherapeutics?
Key investors in Immorna Biotherapeutics include 华创资本.
Will Immorna Biotherapeutics IPO soon?
No public IPO plans have been announced for Immorna Biotherapeutics.
How can I track Immorna Biotherapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Immorna Biotherapeutics's shares on secondary markets.